By the clinical team at Next Step Psychiatry • Lilburn, GA
Since Spravato’s FDA approval in 2019, thousands of patients have received the treatment at psychiatric clinics across the United States. As 2026 progresses, we now have substantial real-world evidence showing how effective Spravato truly is in clinical practice beyond randomized trials. At Next Step Psychiatry in Lilburn, we’re seeing these results firsthand and want to share what the latest data reveals.
Real-World Response Rates
Clinical trial data showed that approximately 50–70% of patients with treatment-resistant depression respond to Spravato. Real-world data from clinics across the country in 2025–2026 is proving even more encouraging. Studies tracking actual patients in psychiatric clinics show response rates of 55–75%, with many clinics reporting even higher rates when combining Spravato with psychotherapy.
Remission rates—meaning depression symptoms resolve substantially—are also impressive. While trial data showed remission in 25–35% of patients, real-world data suggests remission rates of 30–45%. These aren’t just marginal improvements; many patients describe feeling like their depression has lifted completely.
Speed of Response: A Key Advantage
One of Spravato’s defining features is the speed of response. Traditional antidepressants take weeks to work. Spravato works faster. Data from 2026 shows that many patients notice mood improvement within their first week of treatment—some within their first treatment. By week two or three, most responding patients show measurable improvement on standardized depression scales.
This rapid response is profoundly significant for severely depressed individuals. Patients who can’t sleep, eat, or function often report that Spravato gives them the mental and emotional space to engage in therapy, reconnect with loved ones, and begin rebuilding their lives. The hope that comes from rapid improvement is itself therapeutic.
Durability of Response
An important question is whether Spravato’s benefits last. 2026 data from patients who’ve been in treatment for 12 months or longer shows good durability of response. Most patients maintain their improvements with regular maintenance dosing—typically once weekly or every other week after the initial induction phase. Some patients eventually space out their doses further, requiring treatment every 2–3 weeks.
However, Spravato isn’t a permanent cure. Symptom return is common if maintenance treatment stops. This is similar to other chronic conditions—just as a diabetic patient needs ongoing insulin, many TRD patients need ongoing Spravato. The good news is that patients are usually pleased to continue treatment if it’s working, and the commitment is manageable (weekly outpatient visits).
Effectiveness in Different Patient Populations
Real-world 2026 data shows Spravato works across different demographic and clinical groups. Older adults respond well, as do younger patients. Patients with severe depression, moderate depression, and even chronic low-grade depression show response. Patients with depression and co-occurring anxiety often show particularly good response, with both conditions improving.
Patients who previously failed multiple antidepressants respond at rates similar to those who failed fewer medications, suggesting Spravato’s mechanism is truly different from traditional approaches.
Side Effect Profile in Real-World Use
2026 data confirms that Spravato is generally well-tolerated. The dissociative effects during treatment are the primary concern, but most patients adapt well. Some patients describe the dissociative experience as actually helpful—it provides relief from the constant negative thoughts of depression. Dizziness, nausea, and changes in blood pressure during and immediately after dosing occur but are usually mild and resolve quickly.
Long-term side effects have been minimal. Patients don’t report the sexual dysfunction, weight gain, or emotional blunting that can accompany traditional antidepressants. This improved tolerability often leads to better long-term adherence and quality of life.
Cost and Insurance Considerations
2026 has seen gradual improvement in insurance coverage of Spravato. More insurance companies are covering Spravato for treatment-resistant depression after appropriate documentation. Several major Medicaid programs in Georgia and across the country now cover Spravato. However, cost remains a barrier for some—treatment can cost $3,000–$5,000 monthly initially. Many clinics work with patients on payment plans or can direct them to assistance programs.
Spravato in Lilburn and the Atlanta Metro
At Next Step Psychiatry, we’ve been offering Spravato since its approval became available. Our patients from Lilburn, throughout Gwinnett County, and the broader Atlanta metro area are experiencing the real-world benefits reflected in the 2026 data. We carefully evaluate each patient, ensure they meet criteria for treatment-resistant depression, provide thorough psychoeducation, and monitor progress closely. Many of our patients report that Spravato has been life-changing.
The Future
As more data accumulates in 2026 and beyond, we expect even more insights into optimizing Spravato treatment, predicting who will respond best, and potentially using Spravato for conditions beyond treatment-resistant depression. What’s clear now is that for many patients with severe, treatment-resistant depression, Spravato offers real hope and real results.
Call 678-437-1659 to discuss whether Spravato might help you.
This article is for informational purposes only and is not a substitute for professional medical advice. If you or someone you know is in crisis, call 911 or the 988 Suicide & Crisis Lifeline.